VALNEVA USA, INC.

Valneva USA, Inc. specializes in the manufacturing and supply of biological pharmaceutical products, with deep expertise in vaccine development and production, particularly for infectious disease threats such as Japanese encephalitis. The company’s core capabilities center on GMP-compliant biological manufacturing, cold-chain logistics for vaccine distribution, and end-to-end supply chain management for licensed biologics, including the IXIARO vaccine. Their technical proficiency spans cell culture-based production, viral antigen purification, lyophilization, and sterile fill-finish operations for injectable formulations. Valneva’s unique specialization lies in delivering pre-qualified, FDA-licensed vaccines to government agencies under emergency and routine procurement frameworks, ensuring rapid deployment in public health and defense scenarios. The contractor maintains strong, recurring relationships with the Department of Defense, Department of Veterans Affairs, and Department of Justice, primarily supplying critical vaccines for military personnel, veteran health programs, and federal emergency response units. The Department of Health and Human Services also engages Valneva for public health stockpiling and immunization initiatives, while the Department of State procures vaccines for diplomatic and overseas operational needs. These engagements reflect a pattern of trusted, mission-critical supply partnerships focused on biosecurity and force health protection. Valneva’s primary industry focus is in pharmaceutical preparation manufacturing (NAICS 325412) and biological product manufacturing (NAICS 325414), positioning them as a niche provider of licensed biologics rather than diagnostics or general medical supplies. They serve the federal biodefense and global health markets with products requiring stringent regulatory oversight and validated manufacturing processes. As a 2L entity headquartered in Bethesda, Maryland, Valneva USA, Inc. operates as a U.S.-based manufacturer with no federal certifications on record. Their geographic presence supports direct federal supply chain integration, with operations calibrated to meet Defense Logistics Agency and HHS BARDA requirements for vaccine readiness and distribution.